None
Quote | Xynomic Pharmaceuticals Holdings Inc (OTCMKTS:XYNO)
Last: | $2.22 |
---|---|
Change Percent: | 0.0% |
Open: | $2.22 |
Close: | $2.22 |
High: | $2.22 |
Low: | $2.22 |
Volume: | 132 |
Last Trade Date Time: | 05/12/2021 04:56:18 pm |
News | Xynomic Pharmaceuticals Holdings Inc (OTCMKTS:XYNO)
metamorworks/iStock via Getty Images The clinical-stage biotech company, Xynomic Pharmaceuticals (XYNO) announced that it closed a short-form merger with Xu-Nuo Pharma as part of its plans to go private. Xu-Nuo Pharma held ~98% of the outstanding common shares in Xynomic following a...
Headwinds The odds of a SPAC ultimately succeeding aren't good. Newly de-SPACed companies, those that have gone public via a deal with a special purpose acquisition company/SPAC, face brutal headwinds. Sorting through the carnage in data compiled by SPAC Research , 73% of these stocks h...
Message Board Posts | Xynomic Pharmaceuticals Holdings Inc (OTCMKTS:XYNO)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Xynomic Pharmaceuticals Holdings Inc Company Name:
XYNO Stock Symbol:
OTCMKTS Market:
SHANGHAI, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast-T...
SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced the dosing of the first Chinese patient in its on-going global pivotal Phase ...
RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced encouraging interim data from an ongoing Phase 1b study of its lead cand...